, GLOBOCAN. World Health Organization

E. Felip, C. Gridelli, P. Baas, R. Rosell, R. Stahel et al., Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer, Ann Oncol. 1 juill, vol.22, issue.7, pp.1507-1526, 2010.

, Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-SmallCell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials, J Clin Oncol, vol.26, issue.28, pp.4617-4642, 2008.

D. 'addario, G. Pintilie, M. Leighl, N. B. Feld, R. Cerny et al., Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a metaanalysis of the published literature, J Clin Oncol Off J Am Soc Clin Oncol. 1 mai, vol.23, issue.13, pp.2926-2962, 2005.

J. Pujol, F. Barlesi, and J. Daurès, Should chemotherapy combinations for advanced nonsmall cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials, Lung Cancer Amst Neth. mars, vol.51, issue.3, pp.335-380, 2006.

K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata et al., Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.22, pp.3852-3861, 2004.

A. Ardizzoni, L. Boni, M. Tiseo, F. V. Fossella, J. H. Schiller et al., Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis, J Natl Cancer Inst. 6 juin, vol.99, issue.11, pp.847-57, 2007.

J. H. Schiller, D. Harrington, C. P. Belani, C. Langer, A. Sandler et al., Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer, N Engl J Med. 10 janv, vol.346, issue.2, pp.92-100, 2002.

G. V. Scagliotti, P. Parikh, V. Pawel, J. Biesma, B. Vansteenkiste et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol Off J Am Soc Clin Oncol. 20 juill, vol.26, issue.21, pp.3543-51, 2008.

E. Quoix, G. Zalcman, J. Oster, V. Westeel, E. Pichon et al., Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, The Lancet. sept, vol.378, issue.9796, pp.1079-88, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00718837

, Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group, BMJ, vol.311, issue.7010, pp.899-909, 1995.

A. Sandler, J. H. Schiller, and D. H. Johnson, Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer, N Engl J Med, vol.9, 2006.

J. D. Patel, M. A. Socinski, E. B. Garon, C. H. Reynolds, D. R. Spigel et al., PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed Page, p.61

, by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer, J Clin Oncol. 1 déc, vol.31, issue.34, pp.4349-57, 2013.

M. Reck, J. Von-pawel, P. Zatloukal, R. Ramlau, V. Gorbounova et al., Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL, J Clin Oncol. 10 mars, vol.27, issue.8, pp.1227-1261, 2009.

D. H. Lee, K. Park, J. H. Kim, J. Lee, S. W. Shin et al., Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy, Clin Cancer Res. 15 févr, vol.16, issue.4, pp.1307-1321, 2010.

T. S. Mok, Y. Wu, S. Thongprasert, C. Yang, D. Chu et al., Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma, N Engl J Med. 3 sept, vol.361, issue.10, pp.947-57, 2009.

R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol. mars, vol.13, issue.3, pp.239-285, 2012.

J. Yang, Y. Wu, M. Schuler, M. Sebastian, S. Popat et al., Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUXLung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, Lancet Oncol. févr, vol.16, issue.2, pp.141-51, 2015.

T. S. Mok, Y. Wu, M. Ahn, M. C. Garassino, H. R. Kim et al., Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, N Engl J Med. 16 févr, vol.376, issue.7, pp.629-669, 2017.

J. Soria, Y. Ohe, J. Vansteenkiste, T. Reungwetwattana, B. Chewaskulyong et al., Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer, N Engl J Med. 11 janv, vol.378, issue.2, pp.113-138, 2018.

B. Besse, A. Adjei, P. Baas, P. Meldgaard, M. Nicolson et al., ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease, Ann Oncol. 1 août, vol.25, issue.8, pp.1475-84, 2014.

A. T. Shaw, D. Kim, K. Nakagawa, T. Seto, L. Crinó et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med. 20 juin, vol.368, issue.25, pp.2385-94, 2013.

B. J. Solomon, T. Mok, D. Kim, Y. Wu, K. Nakagawa et al., First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer, N Engl J Med. 4 déc, vol.371, issue.23, pp.2167-77, 2014.

A. T. Shaw, T. M. Kim, L. Crinò, C. Gridelli, K. Kiura et al., Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, Lancet Oncol. juill, vol.18, issue.7, pp.874-86, 2017.

J. Soria, D. Tan, R. Chiari, Y. Wu, L. Paz-ares et al., First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet, vol.389, pp.917-946, 2017.

S. Peters, D. R. Camidge, A. T. Shaw, S. Gadgeel, J. S. Ahn et al., Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer, N Engl J Med. 31 août, vol.377, issue.9, pp.829-867, 2017.

H. R. Kim, M. Ahn, C. Yang, J. Han, and J. , Brigatinib vs Crizotinib in patients with ALKinhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 Trial (ALTA-1L). Session plénière présenté à, WCLC, 2018.

A. T. Shaw, S. Ou, Y. Bang, D. R. Camidge, B. J. Solomon et al., Crizotinib in ROS1Rearranged Non-Small-Cell Lung Cancer, N Engl J Med, vol.371, issue.21, pp.1963-71, 2014.

W. K. Decker, R. F. Silva, M. H. Sanabria, L. S. Angelo, F. Guimarães et al., Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. Front Immunol. 2 août, vol.8, 2017.

D. Hanahan and R. A. Weinberg, The Hallmarks of Cancer, Cell. 7 janv, vol.100, issue.1, pp.57-70, 2000.

D. Hanahan and R. A. Weinberg, Hallmarks of Cancer: The Next Generation, Cell. mars, vol.144, issue.5, pp.646-74, 2011.

D. S. Chen and I. Mellman, Oncology Meets Immunology: The Cancer-Immunity Cycle, Immunity. juill, vol.39, issue.1, pp.1-10, 2013.

W. Pao, C. Ooi, F. Birzele, A. Ruefli-brasse, M. A. Cannarile et al., Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer, Cancer Discov. avr, vol.8, issue.4, pp.395-402, 2018.

E. Tartour and L. Zitvogel, Lung cancer: potential targets for immunotherapy, Lancet Respir Med. sept, vol.1, issue.7, pp.551-63, 2013.

A. Goubet, A. Livartowski, and E. Romano, Immunothérapie et cancer du poumon : nouveaux concepts, Rev Mal Respir. juin, vol.35, issue.6, pp.642-51, 2018.

K. A. Hofmeyer, H. Jeon, and X. Zang, The PD-1/PD-L1 (B7-H1) Pathway in Chronic InfectionInduced Cytotoxic T Lymphocyte Exhaustion, BioMed Res Int, 2011.

. Disponible,

S. Yao, S. Wang, Y. Zhu, L. Luo, G. Zhu et al., PD-1 on dendritic cells impedes innate immunity against bacterial infection, vol.113, pp.5811-5819, 2009.

C. Butts, M. A. Socinski, P. L. Mitchell, N. Thatcher, L. Havel et al., Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, Lancet Oncol. janv, vol.15, issue.1, pp.59-68, 2014.

J. F. Vansteenkiste, B. C. Cho, T. Vanakesa, D. Pas, T. Zielinski et al., Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, Lancet Oncol. juin, vol.17, issue.6, pp.822-857, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01868690

L. Ridolfi, O. Bertetto, A. Santo, and E. Naglieri, Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial, Int J Oncol. 24 juin, vol.39, issue.4, pp.1011-1018, 2011.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015.

L. Horn, D. R. Spigel, E. E. Vokes, E. Holgado, N. Ready et al., Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057), J Clin Oncol. 10 déc, vol.35, issue.35, pp.3924-3957, 2017.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015.

D. P. Carbone, M. Reck, L. Paz-ares, B. Creelan, L. Horn et al., First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N Engl J Med. 22 juin, vol.376, issue.25, pp.2415-2441, 2017.

N. A. Rizvi, M. D. Hellmann, J. R. Brahmer, R. A. Juergens, H. Borghaei et al., Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer, J Clin Oncol. 1 sept, vol.34, issue.25, pp.2969-79, 2016.

M. D. Hellmann, T. Ciuleanu, A. Pluzanski, J. S. Lee, G. A. Otterson et al., Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N Engl J Med, vol.31, issue.22, pp.2093-104, 2018.

R. S. Herbst, P. Baas, D. Kim, E. Felip, J. L. Pérez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet. avr, vol.387, pp.1540-50, 2016.

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, pp.1823-1856, 2016.

J. R. Brahmer, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Healthrelated quality-of-life results for pembrolizumab versus chemotherapy in advanced, PDL1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial, Lancet Oncol. déc, vol.18, issue.12, pp.1600-1609, 2017.

G. De-lima-lopes, Y. Wu, S. Sadowski, J. Zhang, R. Rangwala et al., 43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894), J Thorac Oncol, vol.11, issue.10, pp.244-249, 2016.

G. Lopes, Meeting Library | Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ? 1%: Open-label, phase 3 KEYNOTE-042 study. Plenary session présenté à: ASCO, 2018.

L. Gandhi, D. Rodríguez-abreu, S. Gadgeel, E. E. Felip, E. et al., Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med. 31 mai, vol.378, issue.22, pp.2078-92, 2018.

L. Paz-ares, KEYNOTE 407 Pembrolizumab Plus Chemotherapy in Squamous NSCLC-The ASCO Post. ASCO présenté à, 2018.

A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung

, cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet, vol.389, pp.255-65, 2017.

M. A. Socinski, R. M. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy et al., Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med, vol.14, issue.24, pp.2288-301, 2018.

. Papadimitrakopoulou, IMPower 132: PFS and safety results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in stage IV non squamous NSCLC. WCLC présenté à, 2018.

A. Szczesna, Avelumab vs Docetaxel for previously treated advanced NSCLC: primary analysis of the phase 3 JAVELIN Lung, 2018.

R. Govindan, A. Szczesna, M. Ahn, C. Schneider, G. Mella et al., Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.35, issue.30, pp.3449-57, 2017.

S. Antonia, S. B. Goldberg, A. Balmanoukian, J. E. Chaft, R. E. Sanborn et al., Safety and antitumour activity in a phase 1b study of combined checkpoint blockade with anti-PDL1 (durvalumab) and anti-CTLA4 (tremelimumab) in non-small cell lung cancer, Lancet Oncol. mars, vol.17, issue.3, pp.299-308, 2016.

J. M. Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel et al., Immune-related adverse events with immune checkpoint blockade: a comprehensive review, Eur J Cancer. févr, vol.54, pp.139-187, 2016.

S. Baxi, A. Yang, R. L. Gennarelli, N. Khan, Z. Wang et al., Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. The BMJ. 14 mars, vol.360, 2018.

S. Champiat, O. Lambotte, E. Barreau, R. Belkhir, A. Berdelou et al., Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Ann Oncol. avr, vol.27, issue.4, pp.559-74, 2016.

Y. Saito and A. Gemma, Current status of DILD in molecular targeted therapies, Int J Clin Oncol. déc, vol.17, issue.6, pp.534-575, 2012.

S. Kudoh, H. Kato, Y. Nishiwaki, M. Fukuoka, K. Nakata et al., Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study, Am J Respir Crit Care Med. 15 juin, vol.177, issue.12, pp.1348-57, 2008.

M. Ando, I. Okamoto, N. Yamamoto, K. Takeda, K. Tamura et al., Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib, J Clin Oncol Off J Am Soc Clin Oncol. 1 juin, vol.24, issue.16, pp.2549-56, 2006.

M. Delaunay, J. Cadranel, A. Lusque, N. Meyer, V. Gounant et al., Immunecheckpoint inhibitors associated with interstitial lung disease in cancer patients, Eur Respir J. 1 août, vol.50, issue.2, p.1700050, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01819272

O. Abdel-rahman and M. Fouad, Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis, Ther Adv Respir Dis. juin, vol.10, issue.3, pp.183-93, 2016.

O. Akbari, P. Stock, A. Singh, V. Lombardi, W. Lee et al., PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions, Mucosal Immunol. janv, vol.3, issue.1, pp.81-91, 2010.

A. K. Singh, P. Stock, and O. Akbari, Role of PD-L1 and PD-L2 in allergic diseases and asthma, Allergy. févr, vol.66, issue.2, pp.155-62, 2011.

C. Robert, G. V. Long, B. Brady, C. Dutriaux, M. Maio et al., Nivolumab in Previously Untreated Melanoma without BRAF Mutation, N Engl J Med. 22 janv, vol.372, issue.4, pp.320-350, 2015.

V. Gounant, S. Brosseau, C. Naltet, M. Opsomer, M. Antoine et al., Nivolumabinduced organizing pneumonitis in a patient with lung sarcomatoid carcinoma, Lung Cancer. sept, vol.99, pp.162-167, 2016.

. Disponible,

H. Senellart and J. Bennouna, Bevacizumab et hypertension artérielle ou protéinurie : prise en charge, Rev Mal Respir. juin, vol.25, issue.6, pp.767-72, 2008.

, and by The ERS Executive Committee, International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias: This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, vol.165, pp.277-304, 2001.

J. L. Westcott and S. R. Cole, Traction bronchiectasis in end-stage pulmonary fibrosis, Radiology. déc, vol.161, issue.3, pp.665-674, 1986.

S. Piciucchi, S. Tomassetti, C. Ravaglia, C. Gurioli, C. Gurioli et al., From "traction bronchiectasis" to honeycombing in idiopathic pulmonary fibrosis: A spectrum of bronchiolar remodeling also in radiology?, BMC Pulm Med. 23 mai, vol.16, 2016.

C. Kyi, R. D. Carvajal, J. D. Wolchok, and M. A. Postow, Ipilimumab in patients with melanoma and autoimmune disease, J Immunother Cancer, vol.2, issue.1, p.35, 2014.

D. B. Johnson, R. J. Sullivan, P. A. Ott, M. S. Carlino, N. I. Khushalani et al., Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders, JAMA Oncol. févr, vol.2, issue.2, pp.234-274, 2016.

O. Kanai, Y. H. Kim, Y. Demura, M. Kanai, T. Ito et al., Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease, Thorac Cancer. juill, vol.9, issue.7, pp.847-55, 2018.

M. Vétizou, J. M. Pitt, R. Daillère, P. Lepage, N. Waldschmitt et al., Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota, Science, vol.350, issue.6264, pp.1079-84, 2015.

N. Chaput, P. Lepage, C. Coutzac, E. Soularue, L. Roux et al., Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab, Ann Oncol. juin, vol.28, issue.6, pp.1368-79, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01604339